RxDoctor Payments Data

Anthony Lama, MD

Internal Medicine · New Orleans, LANPI 1134161946

Payments from drug & device makers

$455in general payments, 2019–2025

Across 8 payments — averaging $56.84 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Vifor Pharma, Inc.$200
  • Otsuka America Pharmaceutical, Inc.$96
  • Nxstage Medical, Inc.$73
  • AstraZeneca$32
  • Akebia Therapeutics Inc$22
  • OPKO Pharmaceuticals, LLC$18
  • plus $14 from 1 others

What the payments were for

  • Speaking & faculty fees$20044%
  • Food & beverage$14632%
  • Education$10924%

General payments by program year

19
20
21
23
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$455 in reported general payments places this provider in the 50th percentile of 1,528 internal medicine providers in Louisiana.

See all internal medicine providers in Louisiana

Medicare billing

Part B allowed, 2024
$81,297
Medicare patients
111
Services billed
975

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
OzempicSemaglutide50$53,538
JardianceEmpagliflozin20$32,454
LokelmaSodium Zirconium Cyclosilicate20$24,578
EliquisApixaban29$23,335
FarxigaDapagliflozin Propanediol13$16,021
TrulicityDulaglutide13$12,617
Sevelamer Carbonate30$7,763
Paricalcitol40$5,608
VascepaIcosapent Ethyl18$4,623
Nifedipine ErNifedipine91$3,177
Labetalol Hcl65$1,495
Atorvastatin Calcium153$1,311
Midodrine Hcl15$1,150
Chlorthalidone86$1,077
Aspirin-Dipyridamole ErAspirin/Dipyridamole25$1,075

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
AstraZenecaLokelma, Farxiga$32$40,59833 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 50th percentile of 1,528 internal medicine providers in Louisiana.

Other internal medicine in New Orleans

See the full list for Louisiana

Where these figures come from

Is this you, or does something look wrong? →